ConductScience.org, home

Paper29174792

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Schiffenbauer A and 11 others. Semin Arthritis Rheum, 2018. Cited by 51 papers, by iCite.

Cite this record

ConductScience Library. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Papers, record 29174792. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29174792

Download JSON
Disease
dermatomyositis48 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.
PubMed
Journal
Semin Arthritis Rheum
PubMed
Year
2018
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Intramural
PubMed
Citations, by iCite
51
iCite
Relative citation ratio, by iCite
2.58
iCite
Revised in PubMed
2025-05-30
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Schiffenbauer AAdam
2Garg MMegha
3Castro CChristine
4Pokrovnichka AAngelina
5Joe GGalen
6Shrader JJoseph
7Cabalar IVImelda Victoria
8Faghihi-Kashani SSara
9Harris-Love MOMichael O
10Plotz PHPaul H
11Miller FWFrederick W
12Gourley MMark

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Dermatologic AgentsMajor topic
DermatomyositisMajor topic
Immunosuppressive AgentsMajor topic
InfliximabMajor topic
Adult
Cross-Over Studies
Double-Blind Method
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Pilot Projects
Prednisone
Treatment Outcome

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
Z99 ES999999Intramural NIH HHSUnited StatesZ99ES999999PubMedNIH RePORTER
ZIAES101081NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00033891Infliximab (Remicade ) to Treat Dermatomyositis and PolymyositisDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18557829Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls.J Neuroimmunol1995https://conductscience.org/library/papers/8557829PubMed
221132303Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity.Rheumatol Int2012https://conductscience.org/library/papers/21132303PubMed
31090839Polymyositis and dermatomyositis (first of two parts).N Engl J Med1975https://conductscience.org/library/papers/1090839PubMed
49153548Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies.Arthritis Rheum1997https://conductscience.org/library/papers/9153548PubMed
511055823Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis.Clin Rheumatol2000https://conductscience.org/library/papers/11055823PubMed
612824706Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations.Eur Neurol2003https://conductscience.org/library/papers/12824706PubMed
710399751Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies.Neuromuscul Disord1999https://conductscience.org/library/papers/10399751PubMed
818403404Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.Rheumatology (Oxford)2008https://conductscience.org/library/papers/18403404PubMed
922955021Therapeutic advances in myositis.Curr Opin Rheumatol2012https://conductscience.org/library/papers/22955021PubMed
1021926626Clinical trials roundup in idiopathic inflammatory myopathies.Curr Opin Rheumatol2011https://conductscience.org/library/papers/21926626PubMed
1122324944Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.Int J Rheum Dis2012https://conductscience.org/library/papers/22324944PubMed
1222110532The tumor necrosis factor superfamily of cytokines in the inflammatory myopathies: potential targets for therapy.Clin Dev Immunol2012https://conductscience.org/library/papers/22110532PubMed
1323024713Novel approaches in the treatment of myositis and myopathies.Ther Adv Musculoskelet Dis2012https://conductscience.org/library/papers/23024713PubMed
1422588740
Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).
Arthritis Care Res (Hoboken)2011https://conductscience.org/library/papers/22588740PubMed
1521688301A randomized, pilot trial of etanercept in dermatomyositis.Ann Neurol2011https://conductscience.org/library/papers/21688301PubMed
1612610824Defining Clinical Improvement in Adult and Juvenile Myositis.J Rheumatol2003https://conductscience.org/library/papers/12610824PubMed
1710805105Tumor necrosis factor-alpha expression in muscles of polymyositis and dermatomyositis.Acta Neuropathol2000https://conductscience.org/library/papers/10805105PubMed
1827320359Diagnosis and classification of idiopathic inflammatory myopathies.J Intern Med2016https://conductscience.org/library/papers/27320359PubMed
1917165006Polymyositis associated with infliximab treatment for rheumatoid arthritis.Mod Rheumatol2006https://conductscience.org/library/papers/17165006PubMed
2016966313Intra-rater and inter-rater reliability of the 10-point Manual Muscle Test (MMT) of strength in children with juvenile idiopathic inflammatory myopathies (JIIM).Phys Occup Ther Pediatr2006https://conductscience.org/library/papers/16966313PubMed

See all 38 referencesDownload CSV of references

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 51 citations.

PMIDTitleJournalYearIn PapersSource
42760264Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature.Rheumatology (Oxford)2026https://conductscience.org/library/papers/42760264PubMed
42488644Convergent innate immune and regulated cell-death pathways in selected myopathies.Front Immunol2026https://conductscience.org/library/papers/42488644PubMed
41371271Targeted Therapy for Idiopathic Inflammatory Myopathy.J Cachexia Sarcopenia Muscle2025https://conductscience.org/library/papers/41371271PubMed
40787733Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/40787733PubMed
40747756Targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.Cochrane Database Syst Rev2025https://conductscience.org/library/papers/40747756PubMed
40181992The role of monocytes and macrophages in idiopathic inflammatory myopathies: insights into pathogenesis and potential targets.Front Immunol2025https://conductscience.org/library/papers/40181992PubMed
39609094Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.Arthritis Rheumatol2025https://conductscience.org/library/papers/39609094PubMed
38700458Paradoxical and bimodal immune-mediated dermatological side effects of TNF-α inhibitors: A comprehensive review.Skin Res Technol2024https://conductscience.org/library/papers/38700458PubMed
38166943Local injection of infliximab into calcinosis lesions in patients with juvenile dermatomyositis (JDM): a clinical trial.Pediatr Rheumatol Online J2024https://conductscience.org/library/papers/38166943PubMed
37842905A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons.Expert Rev Clin Immunol2024https://conductscience.org/library/papers/37842905PubMed
36538023Impaired muscle stem cell function and abnormal myogenesis in acquired myopathies.Biosci Rep2023https://conductscience.org/library/papers/36538023PubMed
35457124Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.Int J Mol Sci2022https://conductscience.org/library/papers/35457124PubMed
35394612Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options.Neurotherapeutics2022https://conductscience.org/library/papers/35394612PubMed
35091780Coexpression network analysis coupled with connectivity map database mining reveals novel genetic biomarkers and potential therapeutic drugs for polymyositis.Clin Rheumatol2022https://conductscience.org/library/papers/35091780PubMed
34857798Idiopathic inflammatory myopathies.Nat Rev Dis Primers2021https://conductscience.org/library/papers/34857798PubMed
34857780Idiopathic inflammatory myopathies.Nat Rev Dis Primers2021https://conductscience.org/library/papers/34857780PubMed
33842655Environmental triggers of dermatomyositis: a narrative review.Ann Transl Med2021https://conductscience.org/library/papers/33842655PubMed
33614683Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study.Front Med (Lausanne)2021https://conductscience.org/library/papers/33614683PubMed
33530460Monoclonal Antibodies as Neurological Therapeutics.Pharmaceuticals (Basel)2021https://conductscience.org/library/papers/33530460PubMed
33362394Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.World J Gastroenterol2020https://conductscience.org/library/papers/33362394PubMed

See all 36 cited byDownload CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CMPK151727PubTator's text mininghttps://conductscience.org/library/genes/51727NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene
TNF7124PubTator's text mininghttps://conductscience.org/library/genes/7124NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
INFLIXIMABCHEMBL1201581Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201581

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29174792

GET https://conductscience.org/api/papers/v1/29174792/references?page=2